.webp&w=828&q=75)
Arafura Rare Earths is advancing its Nolans project as a major non-China NdPr supplier, supported by strategic offtakes, sector tailwinds, and improving technical momentum, though investors still face key risks including funding, execution delays, and rare earth price volatility.

Life360 delivers powerful subscription and advertising growth, expanding margins and accelerating global penetration. Strong MAU momentum, rising Paying Circles, and a breakout technical setup reinforce the company’s position as a high‑growth digital safety leader.

Pro Medicus (ASX: PME) delivers record revenue growth, expanding margins, and accelerating AI‑driven innovation, reinforcing its global leadership in enterprise imaging and cloud‑based diagnostics.
.webp&w=828&q=75)
Bannerman Energy (ASX: BMN) advances Etango uranium project with CNNC financing, strong early works execution, and rising uranium prices, positioning as a leveraged mid-cap growth play in a buoyant nuclear fuel market.

AVITA Medical is strengthening its commercial position as revenue growth improves, cash burn reduces, and its regenerative medicine portfolio expands. The company’s progress in product adoption and operational efficiency keeps it positioned as a speculative healthcare growth story.

IonDrive (ASX: ION) shares surged 24% to a six-year high after an updated technical and economic evaluation of its IONSolv rare earth recycling process, extending a quarterly rally of nearly 280%. With a first commercial-scale production campaign in North America.
...